Drug Profile
Research programme: immunomodulatory therapeutics - Philogen/Janssen Biotech
Latest Information Update: 09 Aug 2016
Price :
$50
*
At a glance
- Originator Janssen Biotech; Philogen
- Class Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Unspecified